Inflammatory Disease Database to Aid Maker of Ulcerative Colitis and Crohn’s Therapies

Inflammatory Disease Database to Aid Maker of Ulcerative Colitis and Crohn’s Therapies
A collaboration with Spanish company IMIDomics will allow biopharmaceutical company Celgene to identify new targets and biomarkers, support further drug development, and classify patients for clinical trials in inflammatory bowel disease (IBD) and other conditions. The partnership, which allows access to IMIDomics’ extensive inflammatory diseases (IMIDs) database, is expected to help advance Celgene’s candidate in mid-late-stage

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *